Overview
SS-31 (Elamipretide) is a cutting-edge peptide that targets the "power plants" of your cells — the mitochondria. Unlike typical antioxidants that mop up damage after it happens, SS-31 prevents damage at the source.
Why mitochondria matter: Mitochondria produce over 90% of your cellular energy. When they dysfunction — which happens increasingly with age and disease — cells can't work properly, leading to fatigue, organ decline, and accelerated aging.
How SS-31 works: SS-31 concentrates in the inner mitochondrial membrane where it stabilizes cardiolipin, a crucial molecule for energy production. This improves efficiency and dramatically reduces the "exhaust" (reactive oxygen species) that damages cells.
What the research shows:
- Enhances cellular energy production (ATP)
- Protects heart, kidney, and brain tissue in injury models
- May improve exercise capacity and reduce fatigue
- Studied in clinical trials for mitochondrial diseases and heart failure
- Could slow age-related functional decline
Clinical development: Currently being studied for primary mitochondrial myopathy, heart failure, and age-related conditions.
Important to know: SS-31 is not yet FDA-approved. Clinical trials are ongoing for various conditions involving mitochondrial dysfunction.
Sources: Szeto HH, et al. (2014) British Journal of Pharmacology | Karaa A, et al. (2018) Neurology | Sabbah HN, et al. (2016) Circulation: Heart Failure
What the evidence shows
Separated by study type- HumanClinical trials and human studies
- Elamipretide received FDA accelerated approval (Sept 2025) as the first treatment for Barth syndrome (brand name Forzinity) based on the TAZPOWER trial and supporting data. Earlier trials in heart failure (Circ Heart Fail 2018, PMID 29282381) and primary mitochondrial myopathy (Karaa et al., Neurology 2018) reported safety with mixed efficacy signals.
- AnimalRodent and other animal models
- Preclinical models show SS-31 concentrates in the inner mitochondrial membrane, binds cardiolipin, reduces reactive oxygen species, and improves mitochondrial energetics in cardiac ischemia-reperfusion, renal, and neurodegenerative injury models.
- In vitroCell and tissue studies
- Cell assays demonstrate cardiolipin stabilization, restoration of cristae structure, improved ATP production, and reduced oxidative stress in stressed mitochondria.
- UncertainMixed, weak or conflicting data
- Accelerated approval is conditional on confirmatory trials; indications beyond Barth syndrome (heart failure, myopathy, aging) are not approved, and efficacy in those settings remains unproven or mixed.
Key studies & findings
3 studies- 1
FDA granted accelerated approval to elamipretide (Forzinity) as the first treatment for Barth syndrome.
- 2
A randomized, placebo-controlled trial of elamipretide in heart failure with reduced ejection fraction demonstrated safety and favorable signals on cardiac structure/function but did not meet all primary endpoints.
- 3
A phase 2/3 randomized clinical trial followed by open-label extension (TAZPOWER) evaluated elamipretide in Barth syndrome and contributed efficacy/safety data supporting its approval.
Benefits & effects
8 documentedMitochondrial protection
Mental health support
Anti-aging effects
Cellular energy enhancement
Neuroprotection
Cognitive support
Mitochondrial Protection: Stabilizes cardiolipin, enhances ATP
Cardiac Function: LV volume improvements
Side effects & safety
7 reportedSafety noteResearch compound only. Limited human safety data available.
Mild-Moderate side effect
- Onset
- Immediately-hours
- Reversible
- Yes
- Dose-dependent
- Yes
- Management
- Rotate injection sites
Mild side effect
- Onset
- During treatment
- Reversible
- Yes
- Management
- Discontinue if severe; resolves
Mild-Moderate side effect
- Onset
- Throughout
- Reversible
- Yes
- Management
- Supportive care
Headache
Rare systemic effects
Injection site reactions
Dizziness
Limitations & open questions
Approval is accelerated (requires confirmatory trials); trials in heart failure and mitochondrial myopathy showed mixed results; long-term outcomes data are limited; use for general 'mitochondrial health' or anti-aging is off-label and unsupported.
Pharmacology
Small mitochondrial-targeting tetrapeptide (D-Arg-dimethylTyr-Lys-Phe-NH2); administered subcutaneously (Forzinity); selectively partitions into the inner mitochondrial membrane, binds cardiolipin, stabilizes cristae, and improves electron transport efficiency while reducing ROS. Half-life is short, requiring frequent dosing.
Reported research dosing
- Reported
- 40 mg Daily
- Route
- SC
- Half-life
- Variable
Research protocols
| Protocol | Dose | Frequency | Route |
|---|---|---|---|
| General Mitochondrial Support | 5-10mg | Once daily | Subcutaneous |
| Athletic Performance | 10-20mg | Once daily pre-workout | Subcutaneous |
| Clinical Protocols | 40mg | Once daily | Subcutaneous or IV |
| Acute Cardioprotection | 0.25mg/kg/hr | Continuous infusion | Intravenous |
Frequently asked questions
Is SS-31 the same as the FDA-approved Forzinity?
Yes - Forzinity is the approved brand of elamipretide (SS-31), granted accelerated approval in 2025 specifically for Barth syndrome.
Can SS-31 be used for general anti-aging?
No approved indication supports that; approved use is limited to Barth syndrome, with confirmatory trials pending. Other uses are investigational.
Citations
53 sources- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53